Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
To own Neogen stock today, you’d need to believe the company can restore credibility and capture value from its food safety portfolio, even as the fallout from the 3M integration weighs on sentiment. The class action lawsuits and latest earnings disappointments mean the smooth completion of this integration now represents both the biggest short-term catalyst and the sharpest risk to the business, as execution missteps increasingly threaten margin recovery and investor confidence.
One relevant announcement came on April 9, 2025: Neogen trimmed its full-year 2025 revenue guidance to US$895 million, directly attributing the cut to persistent integration-related challenges. This dovetailed with the CEO’s departure, adding more uncertainty for those monitoring if integration setbacks will be resolved or compound, leaving the future trajectory of both margins and growth in question.
But while optimism about synergy benefits once fueled the outlook, fresh questions about Neogen’s ability to overcome...
Read the full narrative on Neogen (it's free!)
Neogen's narrative projects $812.9 million revenue and $106.5 million earnings by 2028. This assumes a 3.6% annual revenue decline and a $591.8 million increase in earnings from the current level of -$485.3 million.
Uncover how Neogen's forecasts yield a $7.50 fair value, a 57% upside to its current price.
Members of the Simply Wall St Community have published two fair value estimates for Neogen between US$7.50 and US$14.15 per share. Still, with ongoing integration risks after high-profile legal and financial setbacks, you will find those views sharply diverge on what could drive recovery or continued pressure for the business.
Explore 2 other fair value estimates on Neogen - why the stock might be worth over 2x more than the current price!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。